Aktis Oncology, Inc. (AKTS)
$18.15+2.31%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $969M
- Beta
- 0.45
- P/E (TTM)
- -17.01
- Short % float
- 975.98%
- Days to cover
- 7.3
- SI change
- +45.0%
- 1W
- -2.00%
- 1M
- -24.19%
- vs SPY 1W
- -3.16%
- vs SPY 1M
- -27.18%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AKTS?
- LOPJLB’s latest quantitative signal on Aktis Oncology, Inc. (AKTS) is SELL. Signals are updated daily.
- What market regime is AKTS in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Aktis Oncology, Inc. (AKTS) do?
- Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidat…